Class I Alleles Are Associated with Clinic-based Migraine and Increased Risks of Chronic Migraine and Medication Overuse
Overview
Authors
Affiliations
Objective: We aimed to evaluate associations of human leukocyte antigen variants with migraine or headache in hospital and population-based settings.
Methods: The case-control study population, aged 30-70, included 605 clinic-based migraine patients in a medical center and 8449 population-based participants in Taiwan Biobank (TWB). Clinic-based cases were ascertained by neurologists. Participants in Taiwan Biobank were interviewed by a structured questionnaire including headache and migraine history; among them, 2394 had headache or migraine history while 6055 were free of headache and served as controls. All subjects were genotyped by Axiom Genome-Wide Single Nucleotide Polymorphism Arrays and imputed for eight classical human leukocyte antigen genes. Human leukocyte antigen frequencies were compared between clinic-based and self-reported patients and controls. We utilized likelihood ratio tests to examine human leukocyte antigen-disease associations and logistic regressions to estimate the effect of human leukocyte antigen alleles on migraine.
Results: Human leukocyte antigen and showed significant associations with clinic-based migraine (-value < 0.05). Human leukocyte antigen, human leukocyte antigen, human leukocyte antigen and human leukocyte antigen were significantly associated with migraine, with age and sex-adjusted odds ratios (95% CIs) of 1.80 (1.28-2.53), 1.50 (1.15-1.97), 1.36 (1.14-1.62) and 1.36 (1.14-1.62), correspondingly. Clinic-based migraineurs carrying human leukocyte antigen or human leukocyte antigen had 1.63 (1.11-2.39) -fold likelihood to have chronic migraine with medication-overuse headache compared to episodic migraine. However, no human leukocyte antigen genes were associated with self-reported headache or migraine in the community.
Conclusions: Human leukocyte antigen class I genetic variants are positively associated with risk of clinic-based migraine but not self-reported migraine or headache and may contribute to migraine chronification and medication overuse.
Tummoszeit I, Olofsson I, Chalmer M, Henriksen A, Aagaard B, Brunak S Headache. 2024; 65(1):124-131.
PMID: 39352055 PMC: 11726007. DOI: 10.1111/head.14784.
Exploring Headaches in Pediatric Behçet Disease: Prevalence, Clinical Impact, and Management.
Santangelo A, Corsello A, Gizzi G, Lancieri M, Diana M, Trucco F J Clin Med. 2024; 13(13).
PMID: 38999225 PMC: 11242365. DOI: 10.3390/jcm13133659.
Altered immunity in migraine: a comprehensive scoping review.
Ha W, Chu M J Headache Pain. 2024; 25(1):95.
PMID: 38844851 PMC: 11157828. DOI: 10.1186/s10194-024-01800-8.
Genetics of migraine: where are we now?.
Grangeon L, Lange K, Waliszewska-Prosol M, Onan D, Marschollek K, Wiels W J Headache Pain. 2023; 24(1):12.
PMID: 36800925 PMC: 9940421. DOI: 10.1186/s10194-023-01547-8.
Tsai M, Tsai C, Liang C, Lin Y, Lin G, Tsai C Front Psychiatry. 2023; 13:1067503.
PMID: 36704746 PMC: 9871634. DOI: 10.3389/fpsyt.2022.1067503.